The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study
View/ Open
Date
2022-09-19Author
Elshafei, Mohamed NabilImam, Yahia
Alsaud, Arwa Ebrahim
Chandra, Prem
Parray, Aijaz
Abdelmoneim, Mohamed S.
Obeidat, Khaldun
Saeid, Razan
Ali, Mohammad
Ayadathil, Raheem
Mohamed, Mouhand F.H.
Abdallah, Ibtihal M.
Mohammed, Shaban
Akhtar, Naveed
Danjuma, Mohammed Ibn Masoud
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Background and purpose: Uncertainty remains regarding the impact of enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke compared to plain aspirin (P-ASA). Hence, this study was designed to investigate the effect of EC formulation on ASA response via evaluating thromboxane B2 (TXB2) levels in patients with suspected or newly diagnosed stroke. Methods: A prospective cohort study on suspected or newly diagnosed ischemic stroke patients who are aspirin-naive was conducted. Patients were received either EC aspirin or plain aspirin for at least 3 days. The primary outcome was the proportion of aspirin non-responsiveness between two groups (level of residual serum TXB2 associated with elevated thrombotic risk (< 99.0% inhibition or TXB2 > 3.1 ng/ml) within 72 h after three daily aspirin doses, while secondary outcomes were the incidence of early gastrointestinal tract (GIT) bleeding with the various aspirin preparations. (Trial registration: Clinicaltrials.gov NCT04330872 registered on 02 April 2020). Results: Of 42 patients, ischemic strokes were confirmed in both P-ASA (81%) and EC-ASA (67%) arms. ASA non-responsiveness showed no significant difference between the two formulations (P-ASA vs. EC-ASA; 28.6% vs 23.8%; P = 0.726). Univariate and multivariate logistic regression analysis showed that patients treated with EC-ASA were more likely to have a lower rate of non-responders compared to P-ASA (unadjusted OR 0.78; 95% CI 0.20, 3.11); with the risk highest in type 2 diabetic patients with HBA1c > 6.5% (adjusted OR 6; 95% CI 1.02, 35.27; P = 0.047). No incidence of GIT bleeding observed throughout the study. Conclusion: A significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies.
Collections
- Medicine Research [1483 items ]
Related items
Showing items related by title, author, creator and subject.
-
Sensitive objective markers for measuring aspirin responsiveness in pregnancy: An explorative scoping review
Azhar, Al-Khulaifi; Khatib, Malkan; Sayed, Gamal; Doi, Suhail A.; Danjuma, Mohammed Ibn-Mas’ud ( Elsevier , 2024 , Article)BackgroundAspirin is frequently used in pregnancy to decrease the risk of developing pre-eclampsia. Studies have highlighted this potential benefit which in theory happens by inhibition of platelet function. However, ... -
An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS)
Elshafei, Mohamed Nabil; Imam, Yahia; Mohamed, Mouhand F.H.; Alsaud, Arwa Ebrahim; Ahmed, Mohamed Sayed; Obeidat, Khaldun; Saeid, Razan; Ali, Mohamed; Abdallah, Ibtihal M.; Parray, Aeijaz Sultan; Danjuma, Mohammed Ibn Masoud... more authors ... less authors ( Wolters Kluwer Health , 2020 , Article)Introduction:Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of cardiovascular risk. We hypothesize that EC formulation based on a previous report may blunt aspirin ... -
The effect of low-dose aspirin on platelet function during pregnancy compared to placebo: An explorative study. A letter to the Editor
Mohammed I., Danjuma; Al-Khulaifi, Azhar; Elshafei, Mohamed Nabil ( Elsevier , 2022 , Article)We read with interest Bij de Weg et al.’s, recent mechanistic report on the inhibitory effect of Aspirin on platelet function in patients with pre-eclampsia [1]. Compared to placebo, this study found that 80 mg of generic ...